Amicus Therapeutics, Inc (FOLD)
Amicus Therapeutics, Inc. (FOLD) is a biotechnology company focused on developing therapies for rare genetic disorders. They specialize in protein misfolding diseases, utilizing both small molecule chaperones and gene therapy approaches to treat conditions such as Fabry disease, Pompe disease, and other lysosomal storage disorders. The company aims to leverage innovative science to address unmet medical needs in the rare disease community.
Company News
Global Pompe disease treatment market is growing steadily, driven by enzyme replacement therapies and improved diagnostic technologies, with ongoing research into gene therapy and small molecule treatments promising more efficient solutions.
Pharmaceutical companies are advancing treatments for rare diseases, with Soligenix leading efforts in developing HyBryte, a promising therapy for cutaneous T-cell lymphoma (CTCL), a rare skin cancer affecting older adults.
Amicus Therapeutics reported strong Q2 2024 results, with revenue up 34% year-over-year and EPS beating estimates. The company's key metrics, including geographic revenues and net product revenues, also showed solid performance.